Giancarlo Comi

Strategies to address the burden of MS from the individual and societal perspectives 2:52
Strategies to address the burden of MS from the individual and societal perspectives
Giancarlo Comi • 27 Jun 2022
The evolving understanding of multiple sclerosis: EBV and silent progression 3:06
The evolving understanding of multiple sclerosis: EBV and silent progression
Giancarlo Comi • 27 Jun 2022
Changing approaches to the diagnosis and treatment of multiple sclerosis 3:08
Changing approaches to the diagnosis and treatment of multiple sclerosis
Giancarlo Comi • 27 Jun 2022
BTK inhibitors for multiple sclerosis: progressive disease and de-escalation 2:22
BTK inhibitors for multiple sclerosis: progressive disease and de-escalation
Giancarlo Comi • 27 Jun 2022
Methods for measuring treatment response and disease progression in MS 6:51
Methods for measuring treatment response and disease progression in MS
Giancarlo Comi • 23 Mar 2022
Progressive MS treatment – what is next? 1:39
Progressive MS treatment – what is next?
Giancarlo Comi • 23 Mar 2022
The future of patient-reported outcomes in progressive MS 1:47
The future of patient-reported outcomes in progressive MS
Giancarlo Comi • 23 Mar 2022
Issues using EDSS to monitor treatment response in progressive MS 2:27
Issues using EDSS to monitor treatment response in progressive MS
Giancarlo Comi • 23 Mar 2022
Learnings from laquinimod in MS 2:31
Learnings from laquinimod in MS
Giancarlo Comi • 28 Sep 2021
The story of laquinimod in multiple sclerosis 4:11
The story of laquinimod in multiple sclerosis
Giancarlo Comi • 28 Sep 2021
Personalized treatment in multiple sclerosis 4:05
Personalized treatment in multiple sclerosis
Giancarlo Comi • 28 Sep 2021
Advantages of ozanimod over previous sphingosine 1-phosphate modulators 4:06
Advantages of ozanimod over previous sphingosine 1-phosphate modulators
Giancarlo Comi • 28 Sep 2021
The importance of early treatment in multiple sclerosis 4:10
The importance of early treatment in multiple sclerosis
Giancarlo Comi • 28 Sep 2021
What does an MS diagnosis mean for patients today? 2:02
What does an MS diagnosis mean for patients today?
Giancarlo Comi • 21 Jun 2021
Work productivity improves in patients with RRMS treated with ocrelizumab 4:56
Work productivity improves in patients with RRMS treated with ocrelizumab
Giancarlo Comi • 21 Jun 2021
Why are B-cells such a valuable target in MS? 3:09
Why are B-cells such a valuable target in MS?
Giancarlo Comi • 21 Jun 2021
The content of VJNeurology is intended for healthcare professionals